Compugen Stock Forecast, Price & News

Compugen (NASDAQ:CGEN) Frequently Asked Questions

Is Compugen a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Compugen in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Compugen stock.
View analyst ratings for Compugen or view top-rated stocks.

How has Compugen's stock price been impacted by COVID-19?

Compugen's stock was trading at $11.83 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CGEN stock has decreased by 64.8% and is now trading at $4.16.
View which stocks have been most impacted by COVID-19.

When is Compugen's next earnings date?

Compugen is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Compugen.

How were Compugen's earnings last quarter?

Compugen Ltd. (NASDAQ:CGEN) posted its quarterly earnings results on Friday, November, 12th. The biotechnology company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.06. During the same period in the previous year, the business earned ($0.09) EPS.
View Compugen's earnings history.

What price target have analysts set for CGEN?

3 brokers have issued 1-year price objectives for Compugen's shares. Their forecasts range from $16.00 to $19.00. On average, they expect Compugen's stock price to reach $17.67 in the next twelve months. This suggests a possible upside of 324.7% from the stock's current price.
View analysts' price targets for Compugen or view top-rated stocks among Wall Street analysts.

Who are Compugen's key executives?

Compugen's management team includes the following people:

• Anat Cohen-Dayag, President, Chief Executive Officer & Director
• Ari Krashin, Chief Operating & Financial Officer
• Henry Adewoye, Chief Medical Officer
• Zurit Levine, Vice President-Technology Innovation
• Tsipi Keren-Lehrer, Vice President-Business Development

What is Anat Cohen-Dayag's approval rating as Compugen's CEO?

2 employees have rated Compugen CEO Anat Cohen-Dayag on Glassdoor.com. Anat Cohen-Dayag has an approval rating of 100% among Compugen's employees. This puts Anat Cohen-Dayag in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Compugen's key competitors?

Some companies that are related to Compugen include Rubius Therapeutics (RUBY), Humacyte (HUMA), Caribou Biosciences (CRBU), Vaxcyte (PCVX), Scholar Rock (SRRK), Immunovant (IMVT), Century Therapeutics (IPSC), BioAtla (BCAB), Icosavax (ICVX), SOPHiA Genetics (SOPH), Vaxart (VXRT), Gritstone bio (GRTS), Tenaya Therapeutics (TNYA), MeiraGTx (MGTX) and Monte Rosa Therapeutics (GLUE).
View all of CGEN's competitors.

What other stocks do shareholders of Compugen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Compugen investors own include Oramed Pharmaceuticals (ORMP), TransEnterix (TRXC), NVIDIA (NVDA), Advanced Micro Devices (AMD), QUALCOMM (QCOM), AbbVie (ABBV), Inovio Pharmaceuticals (INO), Netflix (NFLX), Gilead Sciences (GILD) and Pfizer (PFE).

What is Compugen's stock symbol?

Compugen trades on the NASDAQ under the ticker symbol "CGEN."

Who are Compugen's major shareholders?

Compugen's stock is owned by many different retail and institutional investors. Top institutional investors include Nikko Asset Management Americas Inc. (10.27%), BlackRock Inc. (3.71%), Morgan Stanley (2.37%), Rock Springs Capital Management LP (1.88%), Artisan Partners Limited Partnership (1.17%) and Renaissance Technologies LLC (0.98%).

Which institutional investors are selling Compugen stock?

CGEN stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Nikko Asset Management Americas Inc., Jane Street Group LLC, Renaissance Technologies LLC, Voloridge Investment Management LLC, Marshall Wace LLP, Squarepoint Ops LLC, and Creative Planning.

Which institutional investors are buying Compugen stock?

CGEN stock was purchased by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, BlackRock Inc., UBS Group AG, Geode Capital Management LLC, Trexquant Investment LP, Two Sigma Advisers LP, Raymond James & Associates, and Rock Springs Capital Management LP.

How do I buy shares of Compugen?

Shares of CGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Compugen's stock price today?

One share of CGEN stock can currently be purchased for approximately $4.16.

How much money does Compugen make?

Compugen has a market capitalization of $284.63 million and generates $2 million in revenue each year. The biotechnology company earns $-29.70 million in net income (profit) each year or ($0.40) on an earnings per share basis.

How many employees does Compugen have?

Compugen employs 45 workers across the globe.

When was Compugen founded?

Compugen was founded in 1993.

What is Compugen's official website?

The official website for Compugen is www.cgen.com.

Where are Compugen's headquarters?

Compugen is headquartered at Azrieli Center 26 Harokmim Street Building D, Holon L3, 5885849.

How can I contact Compugen?

Compugen's mailing address is Azrieli Center 26 Harokmim Street Building D, Holon L3, 5885849. The biotechnology company can be reached via phone at (723) 765-8585, via email at [email protected], or via fax at 972-3765-8555.